Trial Profile

A Phase II, Safety, and Efficacy Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Patients With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Tiragolumab (Primary)
Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms SKYSCRAPER-04
Sponsors Roche

Most Recent Events

05 Mar 2025 Status changed from active, no longer recruiting to completed.
07 Feb 2025 Planned End Date changed from 30 Dec 2024 to 28 Feb 2025.
05 Aug 2024 Primary endpoint has not been met. (Independent Review Committee (IRC)-Assessed Objective Response Rate (ORR))

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com